Search research articles
Contact Us
Filters
Showing results (101-110 of 118) with videos related to
Page
of 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2022
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors
Jaleh Fallah, Michael H Brave, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 2020
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or Fusions
Diana Bradford, Erin Larkins, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer
Asma Dilawari, Mirat Shah, Gwynn Ison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2025
FDA Approval Summary: Niraparib Plus Abiraterone Acetate Fixed Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
William F Maguire, Dow-Chung Chi, Sundeep Agrawal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2020
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Preeti Narayan, Sakar Wahby, Jennifer J Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery
Michael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
The Lancet. Oncology
|
July 26, 2021
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials
Jaleh Fallah, Lijun Zhang, Anup Amatya, et al.
The Oncologist
|
November 4, 2020
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer
Mitchell S Anscher, Elaine Chang, Xin Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, <i>ESR1</i>-Mutated Advanced or Metastatic Breast Cancer
Mirat Shah, Hima Lingam, Xin Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
Sonia Singh, Diana Bradford, Somak Chatterjee, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 118) with videos related to
Sort By:
Page
of 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2022
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors
Jaleh Fallah, Michael H Brave, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 2020
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or Fusions
Diana Bradford, Erin Larkins, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer
Asma Dilawari, Mirat Shah, Gwynn Ison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2025
FDA Approval Summary: Niraparib Plus Abiraterone Acetate Fixed Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
William F Maguire, Dow-Chung Chi, Sundeep Agrawal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2020
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Preeti Narayan, Sakar Wahby, Jennifer J Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery
Michael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
The Lancet. Oncology
|
July 26, 2021
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials
Jaleh Fallah, Lijun Zhang, Anup Amatya, et al.
The Oncologist
|
November 4, 2020
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer
Mitchell S Anscher, Elaine Chang, Xin Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, <i>ESR1</i>-Mutated Advanced or Metastatic Breast Cancer
Mirat Shah, Hima Lingam, Xin Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
Sonia Singh, Diana Bradford, Somak Chatterjee, et al.
Page
of 12